---
title: "AI 藥物開發商 Absci 與甲骨文和 AMD 達成合作"
description: "人工智能藥物開發商 Absci 宣佈，與甲骨文和 AMD 合作，加速生成式人工智能驅動的藥物發現進程。公司的藥物發現平台將應用甲骨文的人工智能基礎設施和 AMD 的最新硬件。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/256942506.md"
published_at: "2025-09-11T13:14:10.000Z"
---

# AI 藥物開發商 Absci 與甲骨文和 AMD 達成合作

> 人工智能藥物開發商 Absci 宣佈，與甲骨文和 AMD 合作，加速生成式人工智能驅動的藥物發現進程。公司的藥物發現平台將應用甲骨文的人工智能基礎設施和 AMD 的最新硬件。

人工智能藥物開發商 Absci 宣佈，與甲骨文和 AMD 合作，加速生成式人工智能驅動的藥物發現進程。公司的藥物發現平台將應用甲骨文的人工智能基礎設施和 AMD 的最新硬件。

### Related Stocks

- [ORCL.US - 甲骨文](https://longbridge.com/zh-HK/quote/ORCL.US.md)
- [AMD.US - AMD](https://longbridge.com/zh-HK/quote/AMD.US.md)
- [AMDL.US - GraniteShares 2x Long AMD Daily ETF](https://longbridge.com/zh-HK/quote/AMDL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 'It's Not Good Enough,' Says Analyst About AMD Stock | Analyst Gil Luria from D.A. Davidson expresses skepticism about AMD's upcoming Instinct MI455 accelerator, suggesting it | [Link](https://longbridge.com/zh-HK/news/276091350.md) |
| Summitry LLC Acquires 5,460 Shares of Oracle Corporation $ORCL | Summitry LLC increased its stake in Oracle Corporation (NYSE:ORCL) by 173.7% in Q3, acquiring an additional 5,460 shares | [Link](https://longbridge.com/zh-HK/news/276057017.md) |
| 5 Earnings Trades for the Next 30 Days | The article discusses five stocks to trade in the next 30 days during earnings season, emphasizing a strategy that avoid | [Link](https://longbridge.com/zh-HK/news/275797493.md) |
| PNC Financial Services Group Inc. Has $881.64 Million Stock Holdings in Oracle Corporation $ORCL | PNC Financial Services Group Inc. reduced its stake in Oracle Corporation by 2.6% in Q3, holding 3,134,815 shares valued | [Link](https://longbridge.com/zh-HK/news/276005830.md) |
| 4,049 Shares in Advanced Micro Devices, Inc. $AMD Acquired by Capital CS Group LLC | Capital CS Group LLC acquired 4,049 shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) in Q3, valued at approximately $ | [Link](https://longbridge.com/zh-HK/news/276001896.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。